- Home
- GRC vs TSHA Comparison
GRC vs TSHA Comparison
Compare GRC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRC | TSHA |
|---|---|---|
| Founded | 1933 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GRC | TSHA |
|---|---|---|
| Price | $48.05 | $5.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.22 |
| AVG Volume (30 Days) | 87.5K | ★ 3.5M |
| Earning Date | 02-06-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $678,522,000.00 | $6,310,000.00 |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $4.02 | N/A |
| P/E Ratio | $24.97 | ★ N/A |
| Revenue Growth | ★ 3.19 | N/A |
| 52 Week Low | $30.87 | $1.05 |
| 52 Week High | $52.02 | $6.02 |
Technical Indicators
Market Signals| Indicator | GRC | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 48.63 |
| Support Level | $48.11 | $5.58 |
| Resistance Level | $50.58 | $6.02 |
| Average True Range (ATR) | 1.09 | 0.26 |
| MACD | -0.25 | -0.07 |
| Stochastic Oscillator | 15.83 | 9.88 |
Price Performance
Historical ComparisonAbout GRC Gorman-Rupp Company (The)
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.